GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » 12-1 Month Momentum %

Mind Medicine (Mind Medicine) 12-1 Month Momentum % : 142.46% (As of May. 23, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-23), Mind Medicine's 12-1 Month Momentum % is 142.46%.

The industry rank for Mind Medicine's 12-1 Month Momentum % or its related term are showing as below:

MNMD's 12-1 Month Momentum % is ranked better than
97.97% of 1478 companies
in the Biotechnology industry
Industry Median: -27.315 vs MNMD: 142.46

Competitive Comparison of Mind Medicine's 12-1 Month Momentum %

For the Biotechnology subindustry, Mind Medicine's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mind Medicine's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Mind Medicine's 12-1 Month Momentum % falls into.



Mind Medicine  (NAS:MNMD) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mind Medicine  (NAS:MNMD) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Mind Medicine 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Mind Medicine's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mind Medicine (Mind Medicine) Business Description

Traded in Other Exchanges
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
Executives
Schond L. Greenway officer: Chief Financial Officer C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
Robert Barrow director, officer: Chief Executive Officer C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Dan Karlin officer: Chief Medical Officer C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Carol A Vallone director 490 SUMMER STREET, MANCHESTER MA 01944
Andreas Krebs director 5 GIRALDA FARMS, MADISON NJ 07940
Mark Sullivan officer: Chief Legal Officer 1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Roger Crystal director 445 PARK AVE, 10TH FL., NEW YORK NY 10022
Cynthia W. Hu officer: Chief Legal Officer&Secretary 6440 WINDERMERE, NORTH BETHESDA MD 20852
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
Sarah Y Vinson director C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Stephen L Hurst director C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Miri Halperin Wernli director, officer: Executive President C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Carrie Liao officer: VP, Controller&Acct Principal C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007